Nano-X Imaging (NASDAQ: NNOX), through its U.S.-based subsidiary Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp. to support the deployment of the Nanox.ARC across New England. The agreement, announced on September 8, 2026, enables Associated X-Ray Imaging to market, distribute, and support the FDA-cleared, multisource 3D digital tomosynthesis system, leveraging its regional customer relationships and service infrastructure. This move expands Nanox's U.S. channel partner network and is intended to increase access to the Nanox.ARC in outpatient and community-based clinical settings across targeted markets.
The Nanox.ARC is a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability. It is part of Nanox's broader ecosystem, which includes Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery. By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide.
This distribution agreement is significant for several reasons. First, it signals Nanox's continued commitment to expanding its footprint in the U.S. healthcare market, particularly in the outpatient and community-based settings where the Nanox.ARC can provide more accessible imaging services. This aligns with Nanox's vision to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
For healthcare providers in New England, the partnership could mean improved access to advanced imaging technology that is both affordable and scalable. The Nanox.ARC's 3D tomosynthesis capabilities offer higher resolution images than traditional 2D X-rays, potentially leading to earlier detection of diseases such as breast cancer, osteoporosis, and other chronic conditions. With Associated X-Ray Imaging's established customer relationships and service infrastructure, the deployment of Nanox.ARC systems in outpatient clinics and community health centers could become more streamlined, reducing barriers to adoption for practices that may have previously been unable to invest in such technology.
The broader implications for the medical imaging industry are noteworthy. Nanox's business model, which combines affordable hardware with AI-based software and cloud services, could disrupt traditional imaging markets that have typically been dominated by large, expensive systems. By making advanced imaging more accessible, Nanox is positioned to drive the world's transition to preventive health care, a shift that could have profound impacts on public health outcomes and healthcare costs. Early detection of disease through routine imaging can lead to more effective treatments and better prognoses, potentially reducing the burden on healthcare systems.
Moreover, this partnership reflects a growing trend in healthcare towards decentralized care delivery, where services are provided closer to the patient in community settings. As the U.S. healthcare system continues to evolve, there is an increasing emphasis on preventive care and early intervention. Nanox's approach aligns with these trends, and its expansion in New England could serve as a model for other regions.
While the announcement is a positive step for Nanox and the region, it is important to note that the company's forward-looking statements are subject to risks and uncertainties, as detailed in their SEC filings. Nonetheless, the partnership with Associated X-Ray Imaging marks a tangible milestone in Nanox's strategy to make medical imaging more accessible and affordable, ultimately aiming to improve patient outcomes and advance preventive care.
